| Previous close | 10.70 |
| Open | 10.90 |
| Bid | 10.90 x N/A |
| Ask | 11.30 x N/A |
| Day's range | 10.90 - 10.90 |
| 52-week range | 4.99 - 12.90 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc
The transaction, which took place on December 31, 2023, involved the acquisition of 75,537 shares at a trade price of $8.14 per share. This strategic move has expanded Viking Global's holding to a total of 2,531,829 shares in Verastem Inc, reflecting the firm's confidence in the company's future prospects.
- GuruFocus.com
Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)
On February 6, 2024, Robert Gagnon, a director at Verastem Inc, executed a sale of 9,204 shares of the company.
- Zacks
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.
© 2024 Yahoo. All rights reserved.